国际简称:BLOOD CANCER DISCOV 参考译名:血癌发现
主要研究方向:Multiple 非预警期刊 审稿周期:
《血癌发现》(Blood Cancer Discovery)是一本由NLM (Medline)出版的以Multiple为研究特色的国际期刊,发表该领域相关的原创研究文章、评论文章和综述文章,及时报道该领域相关理论、实践和应用学科的最新发现,旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊,近三年没有被列入预警名单。
Blood Cancer Discovery is an internationally peer-reviewed journal published by the American Association for Cancer Research (AACR), focusing on fundamental, translational, and clinical research of hematological diseases. This journal aims to publish research content with significant discoveries and significant impact in the field of hematology, promoting progress in hematology research and communication. The editorial team of the journal is led by internationally authoritative experts in the fields of blood and cancer research, and is composed of renowned experts from top medical research institutions around the world.
The magazine receives a limited number of articles, ensuring high-quality content, and the art section of the journal is carefully crafted by a professional team. This journal has been indexed by ESCI and is planned to be indexed by SCIE, with an expected high impact factor.
| CiteScore | SJR | SNIP | CiteScore 指数 | ||||||||||||||||||||
| 12.7 | 4.64 | 1.527 |
|
名词解释:CiteScore 是衡量期刊所发表文献的平均受引用次数,是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年(含计算年度)的被引次数除以该期刊近四年发表的文献数。例如,2022年的 CiteScore 计算方法为:2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量 注:文献类型包括:文章、评论、会议论文、书籍章节和数据论文。
| 按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
| 学科:HEMATOLOGY | ESCI | Q1 | 7 / 97 |
93.3% |
| 学科:ONCOLOGY | ESCI | Q1 | 24 / 322 |
92.7% |
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
| 学科:HEMATOLOGY | ESCI | Q1 | 5 / 97 |
95.36% |
| 学科:ONCOLOGY | ESCI | Q1 | 19 / 322 |
94.25% |